ChemicalBook > Product Catalog >Organic Chemistry >Phosphines >NERIDRONATE SODIUM HYDRATE

NERIDRONATE SODIUM HYDRATE

NERIDRONATE SODIUM HYDRATE Suppliers list
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +8613027611063
Email: info@dakenchem.com
Products Intro: Product Name:NERIDRONATE SODIUM HYDRATE
CAS:79778-41-9
Purity:99% Package:100g ,1KG ,5KG 25KG
Company Name: career henan chemical co
Tel: +86-0371-86658258
Email: factory@coreychem.com
Products Intro: Product Name:NERIDRONATE SODIUM HYDRATE
CAS:79778-41-9
Purity:95--99% Package:1KG;1USD
Company Name: Shaanxi Dideu Medichem Co. Ltd
Tel: 18192627656
Email: 1012@dideu.com
Products Intro: Product Name:NERIDRONATE SODIUM HYDRATE
CAS:79778-41-9
Purity:99% Package:1KG;1USD|25KG;USD|100KG;USD
Company Name: Finetech Industry Limited
Tel: 27-87465837
Email: info@finetechnology-ind.com
Products Intro: Product Name:NERIDRONATE SODIUM HYDRATE
CAS:79778-41-9
Purity:98% Package:1g,10g,25g,500g,1kg
Company Name: Dayang Chem (Hangzhou) Co.,Ltd.
Tel: 571-88938639 +8617705817739
Email: info@dycnchem.com
Products Intro: Product Name:Neridronic acid
CAS:79778-41-9
Purity:0.95&0.99 Package:0.1KG;1KG;1000KG Remarks:Hot sales

NERIDRONATE SODIUM HYDRATE manufacturers

NERIDRONATE SODIUM HYDRATE Basic information
Product Name:NERIDRONATE SODIUM HYDRATE
Synonyms:NERIXIA;NERIDRONATE;NERIDRONATE SODIUM HYDRATE;NERIDRONIC ACID;6-AMINO-1-HYDROXYHEXYLIDENE BISPHOSPHONIC ACID;6-amino-1-hydroxyhexane-1,1-diphosphonate;Neridronic;6-Amino-1-hydroxyhexylidene bisphosphonic acid, Neridronic acid, Nerixia
CAS:79778-41-9
MF:C6H17NO7P2
MW:277.15
EINECS:200-258-5
Product Categories:
Mol File:79778-41-9.mol
NERIDRONATE SODIUM HYDRATE Structure
NERIDRONATE SODIUM HYDRATE Chemical Properties
Melting point 245°
Boiling point 600.1±65.0 °C(Predicted)
density 1.658±0.06 g/cm3(Predicted)
storage temp. 2-8°C
solubility H2O: 8 mg/mL, soluble
form solid
pka1.93±0.10(Predicted)
color white
Safety Information
Hazard Codes Xn
Risk Statements 22
WGK Germany 3
MSDS Information
ProviderLanguage
SigmaAldrich English
NERIDRONATE SODIUM HYDRATE Usage And Synthesis
DescriptionNeridronic acid was launched in Italy as intravenous or intramuscular injection for the treatment of osteogenesis imperfecta. It is the first drug launched worldwide for this “orphan disease” characterized by a fragility of the bone. Sufferers risk frequent fractures commencing during infancy, eventually leading to bone deformation and a severe deterioration of the quality of life and life expectancy. Neridronic acid is structurally related to the second generation of bisphosphonates characterized by an amino terminal group and can be synthesized by treating E-aminocaproic acid with phosphoric acid and phosphorous trichloride. Bisphosphonates, synthetic analogs of the endogenous mineral deposition inhibitor pyrophosphate, are extremely potent inhibitors of bone resorption and increase bone mineral density, possibly by inhibiting the activity of osteoclasts and promoting the death of these bone-eroding cells. In vitro, neridronic acid was a poor inhibitor of phagocytosis, but significantly and dose dependently inhibited 8glucuronidase release and superoxide anion production in the rat peritoneal macrophage, two parameters that may have a part in bone resorption. In a clinical study on patients with osteogenesis imperfecta, neridronic acid increased remarkably bone mass in young growing individuals. In adults the changes were less important but still significant.
DescriptionNeridronic acid is an amino bisphosphonate that inhibits farnesyl pyrophosphate (FPP) synthase (IC50 = 388.2 nM in a cell-free assay). It decreases the differentiation of RAW 264.7 cells into osteoclasts in a CRL-12257 co-culture model of osteoclastogenesis when used at concentrations ranging from 0.001 to 100 μM. Neridronic acid (30 μM) inhibits FGF2-induced proliferation and tube formation in human umbilical vein endothelial cells (HUVECs). It reduces the loss of trabeculae and increases bone density in the tibial metaphysis of growing rats when administered subcutaneously at a dose of 0.1 mg/kg per day.
Originatorlnstituto Gentili (Italy)
Brand nameNerixia
Biochem/physiol ActionsNeridronate is a bone resorption inhibitor. It is used to treat Osteogenesis Imperfecta, an "orphan disease" characterized by a fragility of the bone enough to be named the "illness of bones of crystal".
Synthesis6- Aminohexanoic acid (152) was reacted with phosphorus trichloride and phosphorous acid at 85°C, and then water was added to generate free diphosphonic acid 16 in 78% overall yield [59].

Tag:NERIDRONATE SODIUM HYDRATE(79778-41-9) Related Product Information
Zoledronic acid Tacrolimus Ibandronate sodium monohydrate Escin, monosodium salt Alendronate sodium NERIDRONATE SODIUM HYDRATE